Latest Gilead patent challenge comes close to home
News of challenges to US biotech giant Gilead Sciences’ (Nasdaq: GILD) intellectual property in overseas markets is commonplace, with the company conceding patents relating to its hepatitis C drugs in China this week.
Another recent development comes in a court house close to its California home, however, and this time it relates to the HIV/aids drug tenofovir alafenamide (TAF).
Advocacy and patient group the AIDS Healthcare Foundation (AHF) has filed a petition with the Supreme Court of the United States seeking a review of the dismissal of a federal lawsuit filed by AHF in January 2016 against Gilead and other defendants alleging its patent for TAF is invalid because the company manipulated the patent system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze